Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2022	Mar. 31, 2021
Net revenues
Total net revenues		$ 741	$ 4,709
Cost of revenues
Total costs of revenues		491	2,165
Gross profit		250	2,544
Operating costs and expenses
Research and development		2,860	2,431
General and administrative		6,209	6,371
Sales and marketing			1,526
Restructuring and other charges			425
Impairment of assets held for sale		54
Total operating costs and expenses		9,123	10,753
Operating loss		(8,873)	(8,209)
Other income (expense), net
Change in fair value of common stock warrant liability		5,105	(4,027)
Inducement loss on sale of liability classified warrants			(5,197)
Interest expense, net		(15)	(38)
Other income, net		12	61
Net loss and comprehensive loss		$ (3,771)	$ (17,410)
Net loss per share attributable to common stockholders
Basic		$ (0.04)	$ (0.23)
Diluted		$ (0.09)	$ (0.24)
Weighted average shares outstanding
Basic	[1]	84,113,385	76,158,275
Diluted		89,399,261	76,396,078
Product [Member]
Net revenues
Total net revenues			$ 1,729
Cost of revenues
Total costs of revenues			241
Service [Member]
Net revenues
Total net revenues		741	2,980
Cost of revenues
Total costs of revenues		$ 491	$ 1,924

[1] In December 2020 and January 2021, the Company sold pre-funded warrants to purchase up to 5,238,043 and 2,420,910 shares of common stock, respectively. The shares of common stock associated with the pre-funded warrants are considered outstanding for the purposes of computing earnings per share prior to exercise because the shares may be issued for little or no consideration, are fully vested, and are exercisable after the original issuance date. The pre-funded warrants sold in December 2020 and January 2021 were exercised in January 2021 and included in the denominator for the period of time the warrants were outstanding.